iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
Cosm's flagship platform, GynethoticsTM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime.
'Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care,' said Sam Ifergan, Founding Partner at iGan Partners. 'We're excited to support their mission to improve outcomes and quality of life for millions of women.'
'At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning.' – Derek Sham, Founder & CEO of Cosm Medical.
'We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. 'As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders.
GynethoticsTM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery.
About Cosm Medical
Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, GynethoticsTM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at https://www.cosm.care/
About iGan Partners
iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at https://iganpartners.com/
View original content to download multimedia: https://www.prnewswire.com/news-releases/igan-partners-leads-seed-financing-for-cosm-medical-to-advance-personalized-gynecological-devices-302473852.html
SOURCE iGan Partners
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.
Business Wire
2 hours ago
- Business Wire
SugarCRM Named to Constellation ShortList for Top Midmarket CRM Suites
DENVER--(BUSINESS WIRE)-- SugarCRM, provider of the award-winning intelligence-driven sales automation platform, today announced it has been named to the Constellation ShortList™ for Midmarket CRM Suites in Q3 2025. The Constellation ShortList™ portfolio highlights the key players when considering technology investments in key areas and is designed to provide guidance on rapidly changing requirements and customer needs and demands. The Midmarket CRM Suites ShortList was compiled based on Constellation client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Constellation defines midmarket organizations as those that typically have from 250 to 1,000 employees and generate between $250 million and $1 billion in annual revenues. According to the research, in the midmarket CRM space, buyers typically seek one or more products in a suite to support sales force automation, service and support, marketing solutions, and commerce capabilities. Buyers expect analytics to be pervasive, integrated, and easy to use. Sugar Sell, sales-i, Market, and Serve are all part of SugarCRM's platform designed to unify sales, marketing and service through intuitive AI-powered capabilities. Together, these solutions break down the silos that often exist within a business, ensuring a cohesive and efficient approach to customer relationship management and customer success. 'This Constellation ShortList recognizes the strengths of our AI-powered CRM platform,' said David Roberts, SugarCRM Chief Executive Officer. 'Today's organizations demand more than data and insights; they want CRM solutions to direct sellers and customer-facing teams to the right next steps. Sugar delivers AI-powered sales technology that simplifies the complexity that comes from hundreds of customers and thousands of products, improving the productivity and effectiveness of a typical seller.' 'As AI reshapes the business landscape, organizations are under increasing pressure to realize meaningful transformation,' said R 'Ray' Wang, CEO and Founder at Constellation Research. 'In this era of accelerated change, Constellation's ShortList is designed to help companies identify top-performing solutions that drive efficiency and innovation.' Click here to learn more about Sugar's AI-driven solutions for CRM. About the Constellation ShortList Constellation Research advises leaders on leveraging disruptive technologies to achieve business model transformation and streamline business processes. Products and services named to the Constellation ShortList meet the threshold criteria for this category as determined through client inquiries, partner conversations, customer references, vendor selection projects, market share, and internal research. The portfolio is updated at least once per year as the analyst team deems necessary based on market conditions. Disclaimer: Constellation Research does not endorse any solution or service named in its research. About SugarCRM SugarCRM offers software solutions that help marketing, sales, and service teams reach peak efficiency through better automation, data, and intelligence so they can achieve a real-time, reliable view of each customer. Sugar's platform provides leading technology in the sales automation, marketing automation, and customer service fields with one goal in mind: to make the hard things easier. Thousands of companies in over 120 countries rely on Sugar by letting the platform do the work. Headquartered in the San Francisco Bay Area, Sugar is backed by Accel-KKR. For more information about SugarCRM, visit:
Business Wire
2 hours ago
- Business Wire
Firstsource and Guidehealth Partner to Accelerate AI-Enabled Value-Based Care Innovation for Health Plans
MUMBAI, India & DALLAS--(BUSINESS WIRE)-- Firstsource Solutions Limited (NSE:FSL, BSE:532809), a leading global provider of business management services and an RP-Sanjiv Goenka Group company, today announced a strategic partnership with Guidehealth – a pioneer in quality outcomes and value-based care innovation. This collaboration will empower health plans to deliver measurable value for members and providers by accelerating the adoption of next-generation, outcome-driven care models and preventive care. Firstsource's AI-first approach – recognized as a 'Front-Runner' in Generative AI for Healthcare Payers by Everest Group – combines deep domain expertise with its proprietary relAI™ suite and UnBPOᵀᴹ transformation model to help health plans move beyond incremental change. By embedding AI into operations, Firstsource enables streamlined processes, enhanced member engagement, and better health outcomes through intelligent, interoperable platforms that drive agility and measurable results. Guidehealth brings a proven track record in value-based care innovation, helping payers and providers shift to models that reward quality, efficiency, and improved patient outcomes. By combining advanced analytics, clinical expertise, and AI-integrated workflows, Guidehealth supports the implementation and optimization of Medicare Advantage Stars and value-based arrangements – delivering >4 Star performance and measurable improvements in care coordination, cost control, and member satisfaction within the first year. Venkatgiri Vandali, Head, Healthcare & Lifesciences, Firstsource, shared, 'This partnership marks a pivotal step in our mission to redefine healthcare operations. We're proud to support Guidehealth's bold vision for value-based care – uniting their innovation with Firstsource's AI-first, UnBPOᵀᴹ model. By integrating intelligent automation, deep domain expertise, and a human-first mindset, we're enabling health plans to deliver smarter, more personalized, and outcomes-driven care at scale. Together, we're orchestrating a new era of healthcare transformation.' Sanjay Doddamani, MD & CEO, Guidehealth, said, 'Guidehealth is committed to making great healthcare affordable for all by advancing value-based care by combining AI and empathy and delivering tech-enabled healthcare services across the healthcare system. Partnering with Firstsource enables us to combine our expertise in care delivery with cutting-edge AI and digital platforms, creating a powerful ecosystem for health plans and providers. We are excited to deliver measurable value for our clients and their network of doctors and patients.' Firstsource and Guidehealth will offer health plans a comprehensive suite of solutions that: Accelerate successful value-based care adoption through AI, advanced analytics, and clinical expertise Streamline claims and care management using automation and data-driven insights to ensure timely, appropriate care and operational efficiency Enhance member engagement and performance by delivering personalized, tech-enabled experiences that drive measurable improvements in MA Stars, cost, and clinical outcomes across the healthcare value chain Together, Firstsource and Guidehealth offer a powerful, tech-enabled partnership that blends operational excellence with clinical insight. Their combined capabilities help clients transform healthcare delivery at scale – accelerating digital maturity, improving health outcomes, and driving performance in a value-based care environment. About Firstsource Firstsource Solutions Limited, an RP-Sanjiv Goenka Group company (NSE: FSL, BSE: 532809, Reuters: Bloomberg: FSOL:IN), is a global leader providing transformational solutions and services spanning the customer lifecycle across Healthcare, Banking and Financial Services, Communications, Media and Technology, Retail, and other diverse industries. With a global footprint across US, UK, India, Philippines, Mexico, Romania, Turkey, Trinidad & Tobago, South Africa, and Australia, we 'make it happen' for our clients, solving their biggest challenges with hyper-focused, domain-centered teams and cutting-edge tech, data, and analytics. Our inch-wide, mile-deep practitioners work collaboratively, leveraging UnBPO™ - our differentiated approach to reimagining traditional outsourcing - to deliver real-world, future-focused solutions that drive speed, scale, and smarter decision, turning transformation into tangible results for our clients. ( About Guidehealth Guidehealth is dedicated to making great healthcare affordable for all. The company partners with health systems and clinical networks to bring scale and predictable performance to value-based care across all lines of business. Led by physicians, Guidehealth augments existing primary care capacity using innovative AI-based protocols, remotely embedded Healthguides™, and a meticulously designed framework to predict those patients most in need of support in and beyond the exam room. For more information, visit
